Emergent BioSolutions awarded $24m contract modification valued for anthrax vaccine
Emergent BioSolutions has announced that they have been awarded a contract modification valued at approximately $24 million from the United States Biomedical Advanced Research and Development Authority to supply the CYFENDUS® anthrax vaccine for anthrax preparedness efforts. Paul Williams, senior vice president, head of products business, global government & public